MGTX vs OXB.L
MGTX: A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and xerostomia, backed by proprietary viral vector manufacturing and riboswitch gene regulation technology. OXB.L: A leader in the viral vector manufacturing sector, providing essential development and production services for advanced cell and gene therapy treatments.
Side-by-side fundamentals
| Metric | MGTX | OXB.L | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $12.55 | £5.61 | |
| Market cap as of 2026-08-06 | $1.2B | n/a | |
| Net margin as of 2026-08-06 | -151.1% | n/a | |
| Gross margin as of 2026-08-06 | +95.4% | n/a | |
| Operating margin as of 2026-08-06 | -131.9% | n/a | |
| ROE as of 2026-08-06 | -315.6% | n/a | |
| ROA as of 2026-08-06 | -55.0% | n/a | |
| Debt / equity as of 2026-08-06 | 24.92 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | +131.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +141.0% | n/a | |
| Beta as of 2026-08-06 | 1.32 | n/a | |
| 1-year return as of 2026-08-05 close | +62.1% | +20.8% | MGTX higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.